Recent Posts

Pages: 1 ... 8 9 [10]
91
MS - RESEARCH AND NEWS / (Abst.) Assessment of changes in fatigue & cognitive functioning in the absence of progression independent of relapse..
« Last post by agate on October 17, 2025, 08:45:52 pm »

This is an abstract of a study by several authors who are well known in MS research.


From PubMed (October 17, 2025)--"Assessment of changes in fatigue and cognitive functioning in the absence of progression independent of relapse activity":

https://pubmed.ncbi.nlm.nih.gov/41101250/


Recently the PIRA category (progression independent of relapse activity) has been cropping up in MS literature. However, the results of this study seem to indicate that subjects in that category were still progressing since the results showed that


Quote
Participants with no PIRA are still experiencing cognitive worsening and fatigue worsening, and the rate of worsening is similar to those with PIRA.

[/size][/color]
[/size]Wouldn't this fact indicate a need to reassess the PIRA category?[/color]
92
THE PRACTICAL SIDE OF BEING MULTIPLY SCLEROSED / Which doctors are more likely to leave clinical practice?
« Last post by agate on October 16, 2025, 09:24:45 pm »
From MedPage Today (October 10, 2025):

These Physicians Are More Likely to Leave Clinical Practice
93
POLITICS / (New England Journal of Med. editorial) Risk and benefit
« Last post by agate on October 15, 2025, 09:28:52 pm »
From the New England Journal of Medicine (September 24, 2025), editorial, "Risk and Benefit," about vaccines:


https://www.nejm.org/doi/full/10.1056/NEJMe2513817?query=TOC
94
MS - RESEARCH AND NEWS / (Abst.) The effect of DMTs on brain volume loss and disability accumulation in MS...
« Last post by agate on October 14, 2025, 08:37:11 pm »
From PubMed (October 14, 2025)--"The effect of disease-modifying therapies on brain volume loss and disability accumulation in multiple sclerosis: A systematic review and network meta-analysis":


https://pubmed.ncbi.nlm.nih.gov/41080911/


The study involved


Quote
26,247 patients with MS: 21,309 with RMS, and 4938 with progressive MS (PMS).
95
MS - RESEARCH AND NEWS / ECTRIMS 2025 podcasts
« Last post by agate on October 13, 2025, 09:14:33 pm »
ECTRIMS 2025 podcasts (from an e-mail dated October 2, 2025):


https://emu0d.r.sp1-brevo.net/mk/mr/sh/SMJz09SDriOHWPOiXRRAefn8oqHw/J36p67GQH8qw
96
MISCELLANEOUS / How trustworthy is ChatGPT for advice on diet and health?
« Last post by agate on October 12, 2025, 12:07:47 pm »
From Nutrition Action (September 8, 2025):

ChatGPT: Can you trust its advice about diet and health?
97
MS - RESEARCH AND NEWS / ECTRIMS 2025 abstracts
« Last post by agate on October 11, 2025, 03:54:17 pm »
Some of these abstracts, or articles about the presentations, from the recent ECTRIMS 2025 conference have already been posted on MS Speaks but this is a link to all of them.


From Multiple Sclerosis Journal (September 2025):


https://journals.sagepub.com/doi/full/10.1177/13524585251358339
98
TREATMENTS / (ECTRIMS) Report on phase 3 trial of annual-dose rituximab
« Last post by agate on October 10, 2025, 04:08:54 pm »
From Medscape (October 9, 2025):

Annual MS drug effective, affordable, convenient
99
MS - RESEARCH AND NEWS / (Lancet) Effect of repurposed simvastatin on disability progression in SPMS (MS-STAT2)...
« Last post by agate on October 10, 2025, 06:51:27 am »
The entire article in The Lancet (October 10, 2025):

Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): A phase 3, randomised, double-blind, placebo-controlled trial
100
MS - RESEARCH AND NEWS / (Abst.) Ophthalmic conditions in patients with MS
« Last post by agate on October 09, 2025, 08:46:50 pm »
From PubMed (October 9, 2025)--"Ophthalmic conditions in patients with multiple sclerosis":


https://pubmed.ncbi.nlm.nih.gov/41061473/
Pages: 1 ... 8 9 [10]